This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Team Approach

David M. Eddy, MD, PhD

JAMA. 1993;269(14):1849-1855.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE previous article described how a large health maintenance organization (HMO), Kaiser Permanente of Southern California (KPSC), developed a guideline for the use of intravenous radiographic contrast agents for low-risk patients.¹ The principal issue was whether the lower rates of reactions with low osmolar contrast agents (LOCAs) were worth their higher costs compared with high osmolar contrast agents (HOCAs). After estimating the magnitudes of the risks and costs, KPSC determined that they were not; the same resources could provide greater overall benefit to its members if put into other activities, such as screening for cancers of the cervix or breast. The final guideline stated: "For procedures involving intravenous administration, patients who can be determined to be at low risk of having a reaction should receive HOCAs. Patients who have risk factors for a reaction should receive LOCAs." The full guideline contains more details about specific risk factors and pretreatment . . . [Full Text PDF of this Article]

Author Affiliations
Duke University Durham, NC

Footnotes
Reprint requests to Skyline Route, Box 32, Jackson, WY 83001 (Dr Eddy).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?